BI Asset Management Fondsmaeglerselskab A S Trims Stock Position in Insulet Corporation $PODD

Key Points

• BI Asset Management cut its Insulet stake by 52% in the first quarter, selling 15,871 shares and leaving it with 14,663 shares worth about $3.08 million.
• Insulet has seen mixed analyst sentiment: while some firms reiterated bullish views, several slashed price targets; the stock currently carries a Moderate Buy consensus and an average target price of $240.78.
• The company reported better-than-expected Q1 results, with EPS of $1.42 and revenue of $761.7 million, but the stock was trading near $138.97, close to its 1-year low and well below its 1-year high.

BI Asset Management Fondsmaeglerselskab A S lessened its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 52.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,663 shares of the medical instruments supplier's stock after selling 15,871 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Insulet were worth $3,077,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PODD. State Street Corp increased its holdings in Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier's stock valued at $896,916,000 after buying an additional 65,317 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier's stock worth $568,274,000 after acquiring an additional 41,019 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier's stock worth $420,835,000 after acquiring an additional 141,167 shares during the last quarter. Norges Bank bought a new stake in shares of Insulet during the 4th quarter valued at $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Insulet by 3.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier's stock valued at $229,131,000 after acquiring an additional 29,690 shares during the period.

Wall Street Analyst Weigh In

Several research firms have recently commented on PODD. Benchmark restated a "buy" rating on shares of Insulet in a research note on Wednesday, May 27th. Citigroup cut their price target on Insulet from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, May 28th. Leerink Partners reduced their price target on Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Stifel Nicolaus reduced their price target on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. Finally, Wells Fargo & Company decreased their price objective on Insulet from $360.00 to $255.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 6th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and a consensus target price of $240.78.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm's stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $138.97 on Tuesday. The stock has a market cap of $9.63 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm has a fifty day moving average price of $162.97 and a 200-day moving average price of $224.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analysts' expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet's revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.